OTHER RELEVANT INFORMATION

Other Relevant Information

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the communications are available in the Web page of the CNMV.
Previous
2021 2020
Next

2021

March 1, 2021
Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation

February 22, 2021
The Regulations of the Sustainability Committee

January 19, 2021
Grifols begins a new COVID-19 trial containing anti-SARS-CoV-2 polyclonal antibodies

2020

December 16, 2020
Grifols amends certain articles of the Regulations of the Board of Directors and creates a Sustainability Committee

December 15, 2020
Grifols closes the acquisition of Alkahest

November 24, 2020
Grifols strategically expands its operations into Egypt

November 9, 2020
Grifols acquires the remaining 49% of MedKeeper

October 9, 2020
Information on the resolutions approved at the General Meeting of Shareholders on October 9, 2020

October 1, 2020
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

September 7, 2020
Grifols continues strengthening its innovation strategy with the acquisition of Alkahest

September 4, 2020
Notice of Annual General Shareholders' Meeting 2020

July 20, 2020
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million

May 7, 2020
Grifols reinforces its liquidity position to EUR 1,700 million

February 18, 2020
Grifols and the Public Investment Fund of Saudi Arabia to boost plasma medicines self-supply in the region